|
1. Biologie
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
Preventing tumor spread may not improve quality of life [Reuters]
|
|
|
|
|
|
Xie
and colleagues reanalyzed data from nearly 40 randomized trials
involving multiple cancer types. They found that “progression-free
survival,” or the length of time doctors could keep the cancer under
control, was not linked with health-related quality of life.
|
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
Bacterial injections into tumors show early promise for treating cancer [Science]
|
|
|
|
|
|
The
injections appear to activate an immune response that also targets the
tumor. There are still questions about the safety of the approach. But
given how many patients develop resistance or don’t respond to current
cancer treatments, bacterial injections have generated enough interest
that they’re part of a new clinical trial combining bacteria with an
established immune therapy.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
Researchers boost understanding of T-cell therapy in blood cancer [Novartis]
|
|
|
|
|
|
The
study settles the question about whether these relapsed patients whose
tumor cells no longer show signs of the CD19 protein might benefit from
another round of tisagenlecleucel, Orlando says. They won’t benefit,
because the genetic mutations have created versions of the CD19 protein
that can’t be targeted by the therapy.
|
|
|
|
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.2 Pharma
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
The Realities of “Right to Try” [ASH]
|
|
|
|
|
|
“I
don’t know why any company that is committed to gathering evidence to
support a claim of efficacy, that knows it can use the expanded-access
pathway, and that works collaboratively with the FDA would go the ‘Right
to Try’ route,” Dr. Joffe said. “I do not see any positive benefit.”
|
|
|
|
|
|
|
6.12 Ethique
|
|
|
Cancer Center’s Board Chairman Faults Top Doctor Over ‘Crossed Lines’ [NY Times]
|
|
|
|
|
|
“I
have to say, while we pushed back on a lot and discussed a lot, we were
not as effective as we should have been,” Mr. Warner said, according to
a preliminary transcript of a meeting with the hospital’s staff that
was inadvertently emailed by the hospital to a reporter for The New York
Times. “He crossed lines that we should have done more to stop.”
|
|
|
|
|
|
|
6.14 Prix Nobel
|
|
|
|
AACR Congratulates Dr. James P. Allison and Dr. Tasuku Honjo on 2018 Nobel Prize in Physiology or Medicine [AACR]
|
|
|
|
|
|
Allison’s
early research focused on understanding how the immune system defends
the body from pathogens and cancers, with an emphasis on the role of
immune cells called T cells. As part of this work, he discovered the
protein CTLA-4 and showed that it functions to put a brake on T-cell
responses. Honjo’s research identified the protein PD-1 on immune
cells and, after rigorous investigation, showed that it also operates as
a brake on T cells, but that it functions in a different way to CTLA-4.
|
|
|
|
|
|
|
|
|
James Allison and Tasuku Honjo Win Nobel Prize [The Scientist]
|
|
|
|
|
|
In
1996, Allison’s team showed that antibodies against CTLA-4 not only got
rid of cancer, but prevented new tumors from forming in mice. “I
thought this was pretty cool. We patented it,” Allison told The
Scientist earlier this year. “I thought everybody would jump at it.” But
it took him two years of shopping his immunotherapy idea around to
pharmaceutical companies before one finally bit.
|
|
|
|
|
|
|
A Nobel for Immuno-Oncology [In the Pipeline]
|
|
|
|
|
|
Today’s
prize was widely anticipated, and that’s because it’s so well-deserved.
The only regret I have about it – and it’s a regret that shows up every
year during Nobel season – is that the prize tends to make discoveries
like these seem like the work of far fewer people than they really are.
This one has absolutely taken a scientific army, and the campaign
continues.
|
|
|
|
|
|
|
|
6.5 Médecines alternatives/complémentaires
|
|
|
|
6.6 Publications
|
|
|